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ABSTRACT
Introduction. The remarkable intrinsic resistance of Fusarium species to most antifungal agents results in high mortality rates 
in the immunocompromised population.
Aims. This study aimed to investigate the epidemiology, clinical features and antifungal susceptibility of Fusarium isolates in 
patients with invasive fusariosis.
Methodology. A total of 27 patients admitted to a referral hospital from January 2008 to June 2017 were evaluated. Antifungal 
susceptibility testing of isolates was performed by broth microdilution according to the Clinical and Laboratory Standards 
Institute guidelines.
Results. Haematological malignancy was the predominant underlying condition, with an incidence of invasive fusariosis of 
14.8 cases per 1000 patients with acute lymphoid leukaemia and 13.1 cases per 1000 patients with acute myeloid leukaemia. 
The Fusarium solani species complex (FSSC) was the most frequent agent group, followed by the Fusarium oxysporum species 
complex (FOSC). Voriconazole showed the best activity against Fusarium, followed by amphotericin B. Itraconazole showed high 
minimum inhibitory concentration values, indicating in vitro resistance. Clinical FSSC isolates were significantly (P<0.05) more 
resistant to amphotericin B and voriconazole than FOSC isolates.
Conclusion. The present antifungal susceptibility profiles indicate a high incidence of fusariosis in patients with haematological 
malignancy. Species- and strain-specific differences in antifungal susceptibility exist within Fusarium in this setting.
INTROdUCTION
Fusariosis is acquired by the inhalation of conidia, with subse-
quent haematogenous dissemination [1]. Occasionally, the 
skin may be a portal of entry at sites of tissue breakdown or 
onychomycosis [2–6]. Immunocompromised patients are at 
increased risk of developing invasive fusariosis as a result of 
profound and prolonged neutropaenia and/or severe T-cell 
immunodeficiency [7].
While a considerable body of knowledge about Fusarium 
has recently been accumulated in high-resource countries, 
in Latin America only a few groups of scientists have reported 
their experiences, mainly discussing epidemiological surveil-
lance. A number of relevant reviews have recently become 
available, especially regarding the biology, epidemiology and 
clinical aspects of Fusarium species, as well as risk factors 
for infection, host characteristics, treatment and preventive 
strategies.
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The incidence and severity of diseases caused by Fusarium 
species vary according to geographical location. A study 
involving seven European countries described the Fusarium 
fujikuroi species complex (FFSC) as the predominant cause of 
invasive Fusarium infections [8]. This result is similar to that 
reported in a recent study conducted in Turkey, where FFSC 
was the most frequent agent group, followed by the Fusarium 
solani species complex (FSSC) [9]. However, in a study 
conducted in France, FSSC was the most prevalent, followed 
by the Fusarium oxysporum species complex (FOSC), the 
Fusarium dimerum species complex (FDSC) and, more rarely, 
the Fusarium incarnatum–Fusarium equiseti species complex 
(FIESC) [10].
Fusarium species are usually resistant to most antifungals. In 
vitro studies have shown lower minimum inhibitory concen-
trations (MICs) for amphotericin B, nystatin, ketoconazole, 
voriconazole and posaconazole for the Fusarium strains [11]. 
Most Fusarium species exhibit high minimum inhibitory 
concentrations (MICs) to currently used antifungals, espe-
cially azoles [12]. Fusarium species are intrinsically resistant 
to azole antifungals [13]. F. solani, in particular, is intrinsically 
resistant to echinocandins [14]. Recent diagnostic guidelines 
recommend amphotericin B and voriconazole as the drugs 
of choice for the treatment of deep and disseminated infec-
tions [10, 15]. However, Fusarium nygamai and Fusarium 
thapsinum have shown high MICs for all drugs other than 
amphotericin B and natamycin, indicating that identification 
and susceptibility testing of the aetiological agent is essential 
for guiding treatment [16].
Given the paucity of detailed studies on invasive fusariosis, the 
present study was designed to investigate the epidemiology, 
clinical features and antifungal susceptibilities of Fusarium 
isolates in patients with invasive fusariosis.
MeTHOdS
Patients and methods
This study was conducted at Hospital de Clínicas de Porto 
Alegre (HCPA), located in Rio Grande do Sul, the southern-
most state of Brazil. HCPA is a 750-bed university hospital 
that mainly provides care to patients from Porto Alegre, the 
state capital, and nearby towns, but also to those from further-
out areas of the state. The state of Rio Grande do Sul has an 
area of 280 674 km2. The region is unique in Brazil as it is 
characterized by a temperate humid subtropical climate with 
temperatures ranging from 31 to 39 °C in January and from 
28.5 to 1 °C in July. Paediatric patients at HCPA are admitted 
to the 35-bed paediatric unit, while adults are admitted to 
the haematology unit. All patients admitted to these units 
from January 2008 to June 2017 were evaluated. The study was 
approved by the Research Ethics Committee of the institution.
The patients’ medical records were reviewed for data on base-
line characteristics, underlying diseases, treatment modalities, 
outcomes and mycological cultures positive for Fusarium. The 
isolates were obtained from a variety of clinical specimens 
from patients who had participated in a previous study 
approved by the Ethics Committee of the institution (ethics 
approval certificate number CAAE 52251115.4.0000.5327). 
All human subjects gave consent to participate in the study, 
with legal guardians providing consent for those under 18 
years of age.
Patients were categorized according to the revised definitions 
of the European Organisation for Research and Treatment of 
Cancer/Mycoses Study Group (EORTC/MSG) [17]. Invasive 
fusariosis was defined as any case with at least one positive 
blood culture or with the concurrent involvement of two or 
more noncontiguous sites. Neutropaenia was defined as an 
absolute neutrophil count ≤500 cells µl−1.
dNA isolation, PCR and sequencing
Fusarium isolates were cultured on Sabouraud dextrose agar 
plus chloramphenicol (SDA; Difco Laboratories, Detroit, MI, 
USA). Culture plates were incubated at 26 and 37 ˚C and 
observed daily for growth up to 7 days. Initial identification 
of 27 Fusarium isolates was based on macroscopic colony 
morphology and microscopic features in a lacto-phenol 
wet mount preparation according to standard laboratory 
procedures. Final identification of 21 isolates was achieved 
using molecular methods. DNA extraction was performed as 
previously described by Dallé da Rosa et al. [18]. Fragments of 
the translation elongation factor 1-alpha (TEF1α) gene were 
amplified and sequenced using PCR protocols following the 
methods published by Al-Hatmi et al. [12]. Amplicons were 
purified from residual primers and dNTPs enzymatically with 
ExoSAP-IT (USB, Cleveland, OH, USA) and incubated at 37 
°C for 30 min and at 80 °C for 15 min. Cycle sequencing 
was performed using the BigDye Terminator kit version 3.1 
(Applied Biosystems, Inc., Foster City, CA, USA) and the 
extension products were purified with the BigDye XTermi-
nator Purification kit (Applied Biosystems, USA) according 
to the manufacturer’s instructions. Sequencing products were 
analysed on a 3500 Genetic Analyzer (Applied Biosystems, 
USA). Sequencing data visualization and sequence align-
ment were performed with Chromas v2.0 and CLC Main 
Workbench (CLC Bio, Denmark) software, respectively. 
Then, using blast, the consensus sequence was compared 
with reference sequences deposited in GenBank (http://www. 
ncbi. nlm. nih. gov/ genbank/). The obtained sequences were 
deposited in the GenBank database and are shown in Table 1.
Phylogenetic analysis
Retrieved sequences were manually corrected to avoid 
mispaired bases. Consensus sequences were exported as 
FASTA files. Sequences of TEF1α were aligned with ClustalW. 
The best-fit model of evolution was determined by mega X 
[20]. Two maximum-likelihood (ML) phylogenetic trees were 
constructed from TEF1α sequences for FSSC and FOSC, with 
a bootstrap of 1000 repetitions.
Antifungal susceptibility
The clinical isolates were evaluated for susceptibility to vori-
conazole (Sigma-Aldrich, Saint Louis, USA), itraconazole 
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(Sigma-Aldrich, Saint Louis, USA), and amphotericin B 
(Sigma-Aldrich, Saint Louis, USA). MICs were determined 
according to the Clinical and Laboratory Standards Institute 
(CLSI) broth microdilution method for filamentous fungi, 
M38-A2 [21]. The MIC was defined as the lowest concen-
tration that showed 100% inhibition of visible growth as 
compared to the drug-free control well [21]. All tests were 
performed in duplicate. Two reference strains, Candida krusei 
ATCC 6258 and Candida parapsilosis ATCC 22019, were 
included as quality control isolates, with MIC ranges within 
pre-established limits [21]. The results were interpreted 
according to the CLSI epidemiological cutoff values (ECVs), 
as described by Espinel-Ingroff et al. [19], Therefore, consid-
ering >97.5 % of pooled statistically modelled MIC distribu-
tions, the ECVs were defined as follows: for amphotericin 
B, 8 µg ml−1 (FOSC and FSSC); for voriconazole, 16 µg ml−1 
(FOSC) and 32 µg ml−1 (FSSC); and for itraconazole, 32 µg 
ml−1 (FOSC and FSSC).
Statistical analysis
Data were analysed with SPSS version 11.01 for Windows 
(SPSS, Chicago, IL, USA) software package. The groups 
(FSSC and FOSC) were compared with the chi-square test 
or adjusted residual analysis for categorical variables and the 
Mann–Whitney test for nonparametric continuous variables. 
Epidemiological data were compared with the chi-square 
test. The Mann–Whitney test was used to evaluate possible 
differences in MIC values for the different antifungal agents 
tested in the comparisons between FSSC and FOSC. Differ-
ences were considered statistically significant at a P-value of 
≤ 0.05. Prevalence rates were calculated for invasive fusariosis 
Table 1. Minimum inhibitory concentrations (MICs, µg ml−1) of antifungal agents against the F. solani species complex (FSSC) and F. oxysporum species 
complex (FOSC)
Species complex
FSSC GenBank accession no. Code Amphotericin B ECV* Voriconazole ECV* Itraconazole ECV*
N. gamsii MN095848 F5 4 Below 2 Below 128 Above
F. keratoplasticum MN095832 F7 4 Below 8 Below 128 Above
F. petroliphilum MN095835 F10 2 Below 8 Below 128 Above
F. keratoplasticum MN095830 F13 16 Above 32 Equal 128 Above
Neocosmospora sp. MN095846 F14 4 Below 8 Below 64 Above
F. riograndense KX534002 F17 1 Below 8 Below 128 Above
F. keratoplasticum MN095828 F18 2 Below 1 Below 128 Above
F. petroliphilum MN095834 F19 1 Below 2 Below 128 Above
F. keratoplasticum MN095831 F22 16 Above 8 Below 128 Above
F. striatum MN095845 F26 4 Below 16 Below 8 Equal
F. petroliphilum MN095833 F30 1 Below 16 Below 64 Above
F. solani MN095839 F32 16 Above 32 Equal 128 Above
F. keratoplasticum MN095826 F27 16 Above 16 Below 16 Above
F. keratoplasticum MN095827 F31 16 Above 32 Equal 128 Above
F. falciforme MN095823 F6 2 Below 8 Below 128 Above
F. falciforme MN095824 F8 4 Below 8 Below >128 Above
FOSC
Fusarium sp. MN095836 F1 4 Below 1 Below 128 Above
Fusarium sp. MN095838 F4 8 Equal 0.25 Below 128 Above
F. nirenbergiae MN095844 F11 8 Equal 8 Below 128 Above
Fusarium sp. MN095837 F12 2 Below 2 Below 128 Above
F. triseptatum MN095847 F23 1 Below 2 Below 32 Above
*Epidemiological cutoff values (ECVs) of Fusarium according to Espinel-Ingroff et al. [19].
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with Fusarium spp. fungi identified in haematopoietic stem 
cell transplant recipients (n=10), paediatric oncology patients 
(n=8), medical unit patients (n=8) and intensive care unit 
patients (n=1). The estimated incidence of invasive fusariosis 
during the study period (2008–2017) was calculated using 
the total number of admissions to the paediatric unit/haema-
tology unit as the denominator, and rates were expressed as 
the number of cases per 1000 admissions.
ReSUlTS
A total of 27 cases of invasive fusariosis were identified 
from January 2008 to June 2017. All cases were classified as 
‘proven’ based on the EORTC/MSG criteria. Table 2 shows 
the characteristics of the study population. Most patients were 
Caucasian descendants (88.9 %) living in the metropolitan 
area of Porto Alegre. The mean patient age was 22.7 years 
(range, 2–73 years). Infection was more prevalent in males 
(56 %) than in females (44 %). The most commonly affected 
sites were the nasopharynx (33 %) and skin (33 %), especially 
on the lower limbs (62.5 %). Blood culture was positive in 
18.5 % of patients. The most common clinical presenta-
tions of invasive fusariosis were a persistently febrile patient 
(sustained temperature >38 °C) with profound and prolonged 
neutropaenia and disseminated metastatic skin lesions.
Nineteen strains were isolated from skin biopsies of the 
lower limbs and upper limbs, and from fingers, bone frag-
ments, blood, the nasal cavity and ascites fluid; all of them 
from immunosuppressed patients. Twenty-one isolates 
were identified as FSSC [Fusarium keratoplasticum (n=7), 
Fusarium falciforme (n=3), Fusarium petroliphilum (n=3), F. 
solani (n=2), Fusarium striatum (n=1), Fusarium riograndense 
(n=1), Neocosmospora gamsii (n=1) and Neocosmospora sp. 
(n=1)] and FOSC [Fusarium sp. (n=3); F. nirenbergiae (n=1) 
and F. triseptatum (n=1)] (Table 1).
The most common underlying cause of immunodeficiency was 
haematological malignancy (63%), including acute myeloid 
leukaemia (AML, n=7) and acute lymphoid leukaemia (ALL, 
n=7). The incidence of invasive fusariosis was 14.8 cases per 
1000 patients with ALL and 13.1 cases per 1000 patients with 
AML.
All patients received a daily 200 mg dose of fluconazole for 
prophylaxis against invasive fungal infections. Most patients 
were treated with voriconazole and amphotericin B, with 
an overall mortality rate of 40 %. The duration of treatment 
ranged from 5 to 120 days (mean, 22.6 days). Specific therapy 
was not recorded for three patients.
Phylogenetic analysis based on TEF1α sequences was 
conducted in order to position the isolates in the FSSC 
(Fig. 1) and FSOC (Fig. 2). FSSC was the most frequent agent 
group (16 cases, 76.2 %), followed by FOSC (5 cases, 23.8 %). 
Members of the FSSC were the most frequent aetiological 
agents in patients with haematological disease (14/16, 87.5 
%). Our data suggest that these additional species might be 
of importance for human health.
The clinical strains showed resistance to amphotericin B 
(n=5/16, 31.25 %), with ECV >8 µg ml−1. All strains showed 
high MICs for itraconazole. Voriconazole showed the best 
activity against Fusarium, followed by amphotericin B. The 
MICs ranged from 0.25 to 32 µg ml−1 for voriconazole and 
from 1 to 16 µg ml−1 for amphotericin B (Table 1). The clinical 
FSSC isolates were significantly (P<0.05) more resistant to 
amphotericin B and voriconazole than the FOSC isolates.
dISCUSSION
We analysed the relationship of Fusarium species with their 
in vitro resistance profile for three different antifungal agents 
in patients with invasive fusariosis. Determination of the 
pathogen at the species level and its susceptibility to the main 
antifungal agents is important for epidemiological studies 
and for the appropriate management of this difficult-to-treat 
infection. In our sample, FSSC was the most frequently 
encountered agent group, followed by FOSC. This result is 
similar to those reported in studies conducted in southern 
[22] and southeastern Brazil [23, 24], Italy [25, 26], Israel [27] 
and France [10], and may be related to the strong influence of 
European colonization in southern Brazil. Generally, the most 
frequent species causing fusariosis are F. solani, F. oxysporum 
and Fusarium verticillioides [28]. Based on the present results 
and on results from previous studies, it can be stated that, 
once F. solani is identified, clinical management should be 
started with a higher dose of antifungal agents because of its 
resistance, avoiding the use of fluconazole for prophylaxis.
The Fusarium species encountered and the prevalence of 
invasive fusariosis differ according to geographical loca-
tion. The most frequent haplotypes reported in southeastern 
Brazil for invasive fusariosis are FSSC 2-d and FSSC 2 f, with 
these being described in immunosuppressed patients in the 
bone marrow transplant unit and in dermatology outpa-
tients [21] However, in a previous study, FSSC2-h was the 
most commonly isolated species type, followed by FSSC1-a 
[26]. Our results were superior to those of previous studies, 
which showed a prevalence of invasive fusariosis of 0.1 % in 
patients with haematological malignancy, one of 0.24 % in 
haematopoietic stem cell transplant recipients and one of 0.4 
% in patients with AML [25, 26]. In Europe, the incidence of 
Fusarium infections in patients with acute leukaemia is 0.06 
% [29].
It is essential to evaluate the antifungal susceptibility profile 
of Fusarium species in patients with invasive fusariosis 
because most currently available antifungals show poor in 
vitro activity against the members of the FSSC, and fusariosis 
cases involving haematogenous dissemination result in high 
mortality [26]. With regard to azole susceptibility, FSSC 
isolates have shown higher MICs for voriconazole than FOSC 
isolates [19, 30]. Consistent with this, in the present study, 
FSSC isolates were more resistant to voriconazole than FOSC 
isolates. Also, as expected, itraconazole showed no activity 
against Fusarium isolates. In fact, only five isolates had MICs 
≤64 µg ml−1 for itraconazole. Previous studies have shown 
that fluconazole and itraconazole have no activity against 
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Table 2. Characteristics of the 27 patients with Fusarium infection








F5 M C Porto Alegre 34 Nasal AML AMB, VRC, liposomal 
AMB
74 Alive
F7 M C Campo Novo 45 Skin CML VRC (oral) 14 Dead
F10 M C Novo Hamburgo 12 Skin NHL VRC (oral) 45 alive
F13 F C Porto Alegre 54 Skin AML VRC, liposomal AMB 75 Dead
F14 F C Santa Cruz do Sul 15 Nasal ALL VRC (iv) 60 Alive
F17 M C Sapucaia do Sul 15 Nasal ALL VRC (iv and oral) 31 Alive
F18 M C Imbé 22 Skin ALL Deoxy AMB, VRC 5 Dead
F19 M A Porto Alegre 26 Skin AML Liposomal AMB, VRC 45 Alive
F22 F C Porto Alegre 65 Bone AML Liposomal AMB, 
VRC (iv)
10 Dead
F26 M C Uruguaiana 36 Nasal AML Liposomal AMB, 
VRC (iv)
35 Dead
F30 F C São Leopoldo 5 Nasal ALL AMB, VRC, POSA 52 Alive
F32 F A Porto Alegre 13 Nasal ALL Liposomal AMB 120 Alive
F27 F C Novo Hamburgo 31 Blood HL – – Dead
F31 M C Feliz 10 Skin ALL Liposomal AMB, 
VRC (iv)
14 Alive
F6 M B São Jerônimo 18 Nasal Liver transplant AMB, VRC (iv) 9 Dead
F8 F C Santo Antônio da 
Patrulha
73 Skin Kidney 
transplant
AMB 30 Alive
F1 M C Porto Alegre 3 Skin AML VRC 28 Alive
F4 F C Putinga 2 Blood Non-specific 
fever
AMB 14 Alive
F11 M C Viamão 71 Nasal Peripheral 
vascular disease
– – Dead
F12 M C Jabotão dos Guarapés 15 Nasal MN MICA, VRC 60 Alive
F23 M C Porto Alegre 54 Peritoneum Liver cancer and 
HIV
AMB 9 Dead
A1 F C São Lourenço do Sul 34 Blood SEL VRC 8 Alive
A2 F C Porto Alegre 10 Blood ALL VRC 7 Dead
A3 M C Novo Hamburgo 67 Blood Pancreas cancer – – Alive
A4 F C Nova Santa Rita 40 Skin AML AMB, VRC 15 Alive
A5 F C Guaíba 28 BAL Non-specific 
fever
Deoxy AMB 12 Dead
A6 M C Glorinha 61 BAL HIV FLC 13 Alive
A, African descent; ALL, acute lymphoid leukemia; AMB, amphotericin B; AML, acute myeloid leukemia; B, brown; BAL, bronchoalveolar lavage; 
C, Caucasian; CML, chronic myeloid leukemia; F, female; FLC, fluconazole; HL, Hodgkin's lymphoma; M, male; MICA, micafungin; MN, malignant 
neoplasm; NHL, non-Hodgkin's lymphoma; POSA, posaconazole; SEL, spinal epidural lymphoma; VRC, voriconazole.
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Fusarium species [19, 26]. Consistent with the previously 
described observations, F. solani isolated from our patients 
showed higher amphotericin B MIC values than other 
Fusarium species.
Joint guidelines on the treatment of hyalohyphomycoses 
recommend amphotericin B and voriconazole for the treat-
ment of systemic fusariosis [9]. In the present study, a similar 
proportion of patients received monotherapy vs combination 
therapy as initial treatment. In view of the highest rates of 
survival observed in our patients, voriconazole combined 
with intravenous amphotericin B and voriconazole alone were 
the most effective antifungal treatments for invasive fusariosis 
(77.8 and 66.7 %, respectively). With regard to the relation-
ship between MIC, antifungal therapy and outcome, two of 
our patients infected with FSSC who died (F13 and F22) had 
been treated with amphotericin B and voriconazole. Isolates 
from these patients exhibited a broad resistance spectrum 
in susceptibility testing, including reduced susceptibility to 
voriconazole. In general, patients with a favourable outcome 
after antifungal treatment also showed high sensitivity to 
these drugs (83.3 %), with MIC values below the cutoff point 
suggested for their complexes.
Voriconazole was approved for the treatment of Fusarium 
infections in 2002 [10]. It has also been used prophylactically 
against Fusarium spp. [31]. Resistant profiles for amphotericin 
B and voriconazole, which are the currently recommended 
agents in the guidelines for the treatment of invasive fusariosis 
[32], and a late diagnosis may be associated with the high 
Fig. 1. Maximum-likelihood (ML) phylogenetic tree created from TEF1 sequences of 47 Fusarium solani complex (FSSC) sequences based 
on the Hasegawa–Kishino–Yano model. Total alignment length is 691 bp. The tree show values of bootstrap replications higher than 70% 
(n=1000). The tree was rooted with Geejayeesia cicatricum CBS125552. Evolutionary analyses were conducted in mega X [19].
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mortality rate observed in immunocompromised patients 
[33].
Consistent with reports in the literature, most patients with 
invasive fusariosis in the present study had haematological 
malignancy. An interesting feature of Fusarium infection in 
our study was the involvement of the skin and nasopharynx 
and a significant number of positive blood cultures, as 
previously described [34]. Only 7.4 % of our patients were 
HIV-positive, which is an uncommon event in this setting. 
Isolation of Fusarium from the respiratory tract was rare 
among our patients.
Given that Fusarium species are intrinsically resistant to most 
antifungal agents, new approaches are needed for this diffi-
cult-to-treat opportunistic mycosis. This study was relevant 
for establishing the epidemiological features of invasive fusa-
riosis and, more importantly, identifying Fusarium isolates 
at the species level and testing them for antifungal suscep-
tibility in the context of invasive fusariosis. The antifungal 
susceptibilities of isolates causing invasive fusariosis should 
be determined in all cases to ensure the accurate choice of 
drugs for appropriate patient care and successful treatment. 
It is important to increase our knowledge and promote the 
Fig. 2. Maximum-likelihood (ML) phylogenetic tree created from TEF1α sequences of 32 Fusarium oxysporum complex (FOSC) sequences 
based on the Kimura two-parameter model. Total alignment length is 616 bp. The tree show values of bootstrap replications higher than 
60% (n=1000). The tree had Fusarium udum CBS 177.31 as an outgroup. Evolutionary analyses were conducted in mega X [20]
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importance of mycological examination in order to ensure 
appropriate treatment.
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